The Only Futures Trading Guide You’ll Ever Need
Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets.
Download your FREE Technical Analysis Trading Guide Today!
Ivor Royston, insider at Viracta Therapeutics
Ivor Royston Insider Alerts

Get notified the next time Ivor Royston buys or sells Viracta Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Ivor Royston Insider Information

Dr. Royston has served as President, Chief Executive Officer, and Director of Viracta since 2015. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life science venture capital firm. From 1990 to 2000, Dr. Royston also held the position of Chief Executive Officer of the Sidney Kimmel Cancer Center. Prior to that, Dr. Royston was the Director of Clinical Immunology at University of California, San Diego Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed Rituxan, the first approved monoclonal antibody therapy for lymphoma, and which subsequently merged with Biogen to form Biogen Idec, now Biogen. Dr. Royston currently serves on the board of directors of Biocept, Inc. (NASDAQ:BIOC). Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University.

How do I contact Ivor Royston?

The corporate mailing address for Dr. Royston and other Viracta Therapeutics executives is 2533 S. COAST HWY. 101 SUITE 210, CARDIFF CA, 92007. Viracta Therapeutics can also be reached via phone at (858) 400-8470 and via email at [email protected]

Has Ivor Royston been buying or selling shares of Viracta Therapeutics?

Within the last three months, Ivor Royston has bought $44,480.00 of Viracta Therapeutics stock and sold $133,502.00 of Viracta Therapeutics stock. Most recently, Ivor Royston sold 15,833 shares of the business's stock in a transaction on Monday, November 29th. The shares were sold at an average price of $4.82, for a transaction totalling $76,315.06.

Are insiders buying or selling shares of Viracta Therapeutics?

In the last year, Viracta Therapeutics insiders bought shares 1 times. They purchased a total of 8,000 shares worth more than $44,480.00. In the last year, insiders at the sold shares 6 times. They sold a total of 39,867 shares worth more than $191,816.58. The most recent insider tranaction occured on November, 29th when insider Lisa Rojkjaer sold 2,591 shares worth more than $12,488.62. Insiders at Viracta Therapeutics own 3.7 % of the company.

Information on this page was last updated on 11/29/2021.

Ivor Royston Insider Trading History at Viracta Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2021Sell15,833$4.82$76,315.06View SEC Filing Icon  
11/26/2021Sell11,914$4.80$57,187.20View SEC Filing Icon  
11/15/2021Buy8,000$5.56$44,480.00View SEC Filing Icon  
See Full Table

Ivor Royston Buying and Selling Activity at Viracta Therapeutics

This chart shows Ivor Royston's buying and selling at Viracta Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Viracta Therapeutics Company Overview

Viracta Therapeutics logo
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Read More

Today's Range

Now: $4.10
Low: $4.05
High: $4.33

50 Day Range

MA: $6.52
Low: $4.10
High: $8.71

2 Week Range

Now: $4.10
Low: $4.03
High: $24.80

Volume

164,668 shs

Average Volume

426,500 shs

Market Capitalization

$152.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15
The Only Futures Trading Guide You’ll Ever Need
Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets.
Download your FREE Technical Analysis Trading Guide Today!